Privately-held US drug developer Armetheon revealed on Friday that it plans to develop its novel oral anti-coagulant (OAC) tecarfarin for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.
Tecarfarin (formerly ATI-5923) is a long-acting anticoagulant that inhibits vitamin K epoxide reductase (VKOR). Armetheon acquired the asset from the now-defunct ARYx Therapeutics last year.
In these patients, currently available OACs are contra-indicated or inadequate. Tecarfarin, a potentially best-in-class OAC, was designed to avoid cytochrome P450 (CYP) related metabolism that is a major cause of safety and efficacy problems related to the use of warfarin (Coumadin), the current standard of care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze